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Abstract 
Objectives: The association between older-age bipolar disorder and cognitive 
impairments may be mediated by vascular burden. The aim of the study was to 
examine the difference of cognitive function between older people with late-onset 
bipolar disorder (LOBD) and early-onset bipolar disorder (EOBD) by considering 
rigorous vascular risk burden evaluation, comprehensive cognitive tests, and relevant 
biochemistry data. 
Methods: We recruited 95 outpatients aged over 55 with a DSM-IV-TR diagnosis of 
bipolar I disorder. Fifty had LOBD, defined by age of onset after 40. Cognitive 
function was evaluated through a battery of tests assessing verbal memory, 
attention/speed, visuospatial function, verbal fluency, and cognitive flexibility. 
Vascular risk assessments included individual disorders, 10-year Framingham 
cardiovascular risk scores, and serum levels of homocysteine, vitamin B12, folate, 
and triiodothyronine. 
Results: No differences were observed between LOBD and EOBD on any cognitive 
test after adjusting for potential confounders. In addition to age and educational years, 
multiple linear regression analyses indicated significantly negative associations 
between serum homocysteine levels and cognitive performances in attention, 
psychomotor speed, verbal memory, and executive function. 
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Conclusions: Among older people with bipolar disorder, LOBD is not associated with 
more cognitive dysfunction in this study. However, higher serum homocysteine levels 
were significantly associated with worse cognitive performance in this particular 
group. Clinicians therefore have to pay attention to the cognitive function in older 
bipolar patients with higher levels of homocysteine. 
 
Keywords: age of onset; Framingham risk score; homocysteine; neurocognitive 
performance; older-age bipolar disorder 
 
Key points 
‧ About one third of older patients with bipolar disorder have cognitive impairment. 
‧ This study found that higher serum levels of homocysteine were significantly 
associated with worse cognitive performance in attention, psychomotor speed, 
verbal memory, and executive function among older patients with bipolar disorder. 
‧ Late-onset bipolar disorder was not associated with more cognitive dysfunction in 
this study. This may be due to similar cardiovascular risk between late- and 
early-onset bipolar disorder. 
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1. Introduction 
   Bipolar disorder (BD) is a severe mental disorder characterized by recurrence of 
multiple manic or depressive episodes. In addition to the mood burden, patients with 
BD also suffer from several unfavorable outcomes, including high levels of medical 
comorbidities and cognitive deficits.1-3 Studies have repeatedly shown that at least one 
third of older patients with euthymic BD have cognitive impairments.4-6 A recent 
meta-analysis concluded that history of BD was associated with an approximately 
two-fold increased risk of dementia.7 However, different risk factors of cognitive 
impairment have been shown for this specific group, including aging effects,6,8 
unhealthy lifestyle,9 reduced cognitive reserve,10,11 and high burden of vascular 
comorbiditie.12,13 The underlying causal pathways are poorly understood. 
    In the literature, late-onset bipolar disorder (LOBD) is considered to be different 
from early-onset BD (EOBD) with respect to the pathophysiology and clinical 
presentation.3 Compared to patients with EOBD, those with LOBD are found to have 
more cerebrovascular diseases,14 and more severe cognitive impairment.15,16 However, 
evidence from other researches does not show more cognitive deficits in LOBD,17,18 
which was supported by that cognitive impairment in older patients with BD may be 
related to the length of BD illness and number of hospitalizations.13,19 Neuroimaging 
studies also have indicated a negative correlation between gray matter volume and 
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length of BD illness in older patients with BD.20 Altogether, these findings suggest 
that age of onset may not be a reliable predictor of cognitive dysfunction in older 
patients with BD. 
    Higher vascular burden has been shown to be the robust risk factor for cognitive 
deficits in general population21,22 as well as in older patients with BD.13 Since LOBD 
has been found to be more related to vascular diseases,18,23 the association between 
LOBD and cognitive impairments may be mediated by the vascular burden. However, 
previous studies did not find that LOBD patients with more severe cognitive 
impairment have a significantly higher cerebrovascular disease index.15 One possible 
explanation for the negative findings may be due to the measures used to assess the 
vascular risk factors. For example, the Framingham cardiovascular risk score model 
has been demonstrated as a valid tool to predict cognitive deficits in general 
population24,25 but has not been used in studies of patients with LOBD. In addition, 
biomarkers, such as serum levels of homocysteine, vitamin B12, folate, and 
triiodothyronine, which are potential risk factors for both cerebrovascular diseases 
and cognitive dysfunction26-28 have rarely been examined in LOBD. 
    Considering the inconsistent results in the literature, the aim of the study was to 
re-examine the difference of cognitive function between older people with LOBD and 
EOBD by rigorous vascular risk burden evaluation, carrying out comprehensive 
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cognitive tests, using newer definition of LOBD proposed by International Society for 
Bipolar Disorders Task force3 and relevant biochemistry data. In order to assess the 
vascular risk burden more comprehensively compared to the prior studies,13,15,18 we 
applied a series of vascular risk assessments including the individual cardiovascular 
disease, 10-year Framingham cardiovascular risk scores, and serum biomarkers such 
as homocysteine, vitamin B12, folate, and triiodothyronine. 
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2. Methods 
2.1 Participants 
We recruited older people with BD from the outpatient psychiatric services of four 
hospitals in Taipei City, and participants received a structured interview for diagnosis, 
relevant demographic and clinical data, laboratory examination, and a series of 
cognitive tests. 
Inclusion criteria for the participants were as follows: (1) age≧55 years; (2) a 
primary diagnosis of bipolar I disorder (BD-I) confirmed by two research 
psychiatrists (S.C.L and C.C.C) according to the Structured Clinical Interview for 
DSM IV-TR Axis-I Disorder (SCID); and (3) capacity to provide informed consent. 
Exclusion criteria were: (1) severe or acute medical illness within the 3 months 
preceding the study; (2) neurological disorders such as delirium, Parkinson’s disease, 
aphasia or multiple sclerosis; (3) dementia or a Mini-Mental State Examination 
(MMSE) score <17;29 (4) alcoholism defined by an Alcohol Use Disorders 
Identification Test score ≧8 in males or ≧6 in females;30 or (5) electroconvulsive 
therapy in the preceding year. All participants provided written informed consent, and 
the study was approved by the institutional review boards of Taipei City Hospital, 
Taipei Medical University-Wan Fang Hospital, Cathay General Hospital, and Mackay 
Memorial Hospital. 
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2.2 Exposure and covariate ascertainment 
For all participants, a structured questionnaire was used to collect demographic 
and health-related factors, including age, sex, duration (years) of education, current 
cigarette smoking status, psychiatric history, physical health problems, and current 
pharmacotherapy. In addition, the Young Mania Rating Scale (YMRS)31 and 17-item 
Hamilton Depression Rating Scale (HDRS)32 were applied to measure the severity of 
manic and depressive symptoms, respectively. In this study, the onset of BD-I was 
defined as the first occurrence of affective symptoms, either depression or mania, 
which caused severe impairment of a participant’s psychosocial function or resulted 
in psychiatric hospitalization. With the considerations that patients with BD actually 
have earlier onset of medical diseases and shorter life span, we used the 40 years-old 
as the cut-off age for EOBD and LOBD as recently proposed by International Society 
for Bipolar Disorders Task force.3 
To evaluate general health status, self-reported history of the following 
symptoms/disorders was ascertained: angina, previous stroke, arthritis, asthma, bowel 
problems, cough, diabetes, poor eyesight, headaches, poor hearing, previous heart 
attack, hypertension, skin problems, and insomnia;33,34 the total number of these 
symptoms/disorders was calculated. In addition, each participant also underwent 
measurement of blood pressure, body weight, and body height. Blood samples were 
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collected between 6:00 a.m. and 12:00 a.m. following overnight fasting. Serum 
homocysteine was measured by Novel enzyme cycling assay, and triiodothyronine 
was carried out by Chemiluminescence. Electrochemiluminescence assays were 
applied to analyze the levels of vitamin B12 and folate. As an overall measure of 
vascular risk status, 10-year Framingham risk scores were calculated from age, gender, 
current status of cigarette smoking, diabetes mellitus, treatment of hypertension, 
systolic blood pressure, and blood levels of high-density lipoprotein-cholesterol.35 
2.3 Assessment of cognitive function 
After enrollment, participants were administered the Mini-Mental State 
Examination (MMSE) as well as a series of the following cognitive tests: (1) word list 
subtest of Wechsler Memory Scale-III (WMS-III; verbal memory); (2) color trail 
test-1 (CTT-1; attention and psychomotor speed); (3) CTT-2 (cognitive flexibility and 
executive function); (4) block design score from the WAIS-III (visuospatial 
processing); (5) verbal fluency (semantic verbal fluency); (6) digit symbol 
substitution test (attention and psychomotor speed). In addition to global cognitive 
function from the MMSE, the following eight cognitive parameters were selected for 
final comparisons based on their theoretical representativeness of cognitive domains, 
observed sensitivity to age and education, and factor analysis36 : total immediate 
recall, delayed recall, and recognition from word list subtest of WMS-III; CTT-1 
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completion time and CTT-2 completion time from CTTs; block design score from the 
WAIS-III; verbal fluency score from the fruit naming test; and digit symbol 
substitution test score from WAIS-III. 
2.4 Statistical analyses 
Comparisons between EOBD and LOBD groups were analyzed using independent 
sample t tests or Mann-Whitney U tests when explanatory variables were continuous. 
Pearson’s χ2 tests or Fisher’s exact tests were applied to comparisons of categorical 
variables. Multiple linear regressions were separately performed to examine the effect 
of EOBD and LOBD on individual cognitive parameter scores (dependent variables). 
Bearing in mind the limited sample size and number of potential covariates, only 
those with a clear potential impact on the associations between exposure and outcome 
(defined as p-value≦0.2 when individual variable was put into simple linear 
regression to test its effect on the association between EOBD/LOBD and individual 
cognitive test ) were in the final model. Through this, the variables adjusted in the 
regression model were age, gender, years of education, duration of illness, 10-year 
Framingham cardiovascular risk scores, and serum levels of homocysteine and 
triiodothyronine. Data analyses were performed using SPSS version 17.0 software, 
and statistical significance was defined as p-values smaller than 0.05 (two-sided). 
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3. Results 
3.1 Inclusion of patients 
   Ninety-seven older adults with BD were enrolled in this study. Two of the 
participants did not complete the whole assessment and data from 95 participants 
were thus analyzed: 45 with EOBD and 50 with LOBD. 
3.2 Demographic and clinical characteristics 
Table 1 summarizes comparisons of demographic and clinical variables between 
the two groups. No significant differences were found with respect to age, gender, 
duration of education, severity of manic or depressive symptoms, family history of 
psychosis or dementia, or different categories of psychotropic treatments. Compared 
to EOBD, participants with LOBD had lower diastolic pressure and lower levels of 
homocysteine, but had higher levels of cholesterol. In addition, those with LOBD had 
lower body mass index and higher triiodothyronine levels at borderline significance 
levels. There was no difference of Framingham risk scores between EOBD and 
LOBD groups (mean±SD; 17.5±11.2 vs. 20.3±13.5, p=0.338). The correlations 
between serum homocysteine levels and other variables were examined. 
Homocysteine levels were not significantly correlated with age (γ=0.19, p=0.279) or 
educational years (γ=0.05, p=0.775), nor with other demographic and clinical 
variables. 
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[Insert Table 1 about here] 
 
 
3.3 Cognitive performance 
Table 2 summarizes comparisons of cognitive test scores between the two groups. 
Participants with LOBD had similar performance in every cognitive test to those with 
EOBD. 
 
[Insert Table 2 about here] 
 
3.4 Impact of explanatory variables on individual cognitive tests 
When multiple linear regression analyses were separately performed for 
individual cognitive parameters to examine the impact of potential factors on 
associations of interest (Table 3), LOBD was not significantly associated with 
performance on any cognitive parameter. In contrast, age was positively associated 
with the scores of CCT-2, and negatively associated with the scores of block design 
and DSST. Years of education were positively associated with the scores of total 
immediate recall, delayed recall, recognition, block design, verbal fluency, DSST, and 
MMSE, and were negatively associated with the scores of CCT-1 and CCT-2. Further, 
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serum levels of homocysteine were positively associated with the scores of CCT-1, 
and were negatively associated with the scores of delayed recall, verbal fluency, and 
DSST. Duration of illness was negatively associated with the scores of delayed recall. 
 
[Insert Table 3 about here] 
 
In addition, we conducted an analysis using 50 years-old as the cut-off point for 
LOBD. The results are nearly the same with cut-off point set as 40 year-old for LOBD. 
It showed that serum levels of homocysteine were positively associated with the 
scores of CCT-1 (ß=0.29, p=0.012), and were negatively associated with the scores of 
delayed recall (ß=-0.27, p=0.023), verbal fluency (ß=-0.24, p=0.047), and DSST 
(ß=-0.25, p=0.013) in multiple linear regression model. Age was positively associated 
with the scores of CCT-2 and negatively associated with the scores of block design 
and DSST. Years of education were positively associated with the scores of total 
immediate recall, delayed recall, recognition, block design, verbal fluency, DSST, and 
MMSE, and were negatively associated with the scores of CCT-1 and CCT-2. No 
associations were found between cognitive test parameters and gender, LOBD, 
Framingham risk score, and serum triiodothyronine levels. 
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4. Discussion 
   One of the principal findings in the present study was that the performance of 
cognitive function in older patients with LOBD (i.e. defined by an onset above age 40 
years) was not different from those with EOBD. The lack of association between age 
of onset and cognitive dysfunction is in line with some of prior reports17,18 but not 
with others suggesting greater cognitive impairment in people with later age of BD 
onset.15,16 Although we adopted 40 year-old as a decreased cut-off age for LOBD as 
proposed by the International Society for Bipolar Disorder Task force, the results of 
study interest are nearly the same as cut-off age of 50 year-old for LOBD in this 
sample. Previously, cardiovascular risk/diseases have been suggested to play an 
important role in the cognitive impairment in LOBD.3 Our recent neuroimaging study 
found that one third of older BD patients with onset prior to the age of 40 years (i.e. 
EOBD) had cerebral infarction or old stroke.37 The findings suggest that even older 
patients with EOBD are at a high risk of cerebrovascular diseases. In this study, 
compared to patients with LOBD, those with EOBD had similar Framingham risk 
scores and higher diastolic pressure but lower cholesterol levels. The similar 
cardiovascular risks/diseases between LOBD and EOBD groups in our sample might 
play a role for the lack of difference in cognitive function between the two groups. 
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In this study, in addition to age and education, the most consistent and significant 
finding was that higher serum homocysteine levels were significantly associated with 
worse performance in cognitive measures, including attention and psychomotor speed 
(CTT-1 and DSST), verbal memory(delayed recall), and executive function(verbal 
fluency and DSST). Among a variety of cognitive domains, executive dysfunction and 
verbal memory impairment are the cognitive deficits most consistently observed in 
patients with BD.4-6,8 Prior studies of younger population with BD have also 
demonstrated that increased homocysteine levels were associated with cognitive 
deficits, particularly verbal learning, delayed memory, and executive function.38-40 In 
addition, the adverse impact of homocysteine on cognition tended to be greater with 
the aging in patients with BD.38 Taken together, our study was consistent with the 
previous researches suggesting that the elevated homocysteine levels could exert 
detrimental effects on the neurocognitive outcomes in patients with BD across the 
adult lifespan. Higher homocysteine levels in EOBD group may be another 
explanation for no difference of cognitive function between LOBD and EOBD groups 
in our study. In the present study, no significant association was found between global 
cognitive function, represented by MMSE score, and homocysteine levels. Whether 
homocysteine is consistently associated with some specific cognitive domains, such 
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as attention, psychomotor speed, verbal memory and executive function, as suggested 
in this study, needs further investigation. 
The mechanisms underlying the association between elevated serum levels of 
homocysteine and cognitive dysfunctions in older patients with BD are unclear. In 
previous studies, serum homocysteine was found to be elevated in acute manic 
episodes of BD.41 A recent meta-analysis has concluded that serum homocysteine 
levels are elevated in patients with BD even during the euthymic state.42 These 
findings suggest that homocysteine is both a trait and state biomarker for patients with 
BD. In the studies of elderly general population, the serum levels of homocysteine 
over 11umol/L were found to be associated with the increased risk of dementia and 
atrophy of medial temporal lobe.43,44 The elevated levels of homocysteine potentially 
lead to cognitive dysfunctions due to the activations of inflammatory and oxidative 
stress pathways or the reactivations of cholinergic metabolism45,46 as well as being a 
potential vascular risk factor itself.47 In our study, the mean serum levels of 
homocysteine in either LOBD or EOBD group were actually above 11umol/L, and 
therefore may account for the link to cognitive dysfunctions. 
    In line with previous studies,2,6,8 our data confirmed that increased age was 
associated with cognitive dysfunctions in patients with BD. In particular, the negative 
association between age and DSST performance in our multivariate analyses was 
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similar to that reported by Lewandowski et al.,6 indicating particular impairments of 
information processing speed in aged people with BD. Longer duration of education 
was associated with better performance on all cognitive function domains in our 
participants. Recently, large-sample studies in BD have reported that higher cognitive 
reserve is associated with better psychosocial functioning and cognitive performance 
with respect to processing speed, working memory, verbal and visual memory, and 
executive function.10,11 In the present sample, the mean years of education were 
11.3+4.1 and 9.9+4.1 for EOBD and LOBD, respectively. The lengths of education in 
our participants were similar to those of other Taiwanese samples,2,5 although 
relatively shorter than those reported in Western BD populations.4,6,13,15 Considering 
lower educational levels in Eastern older populations with BD, utilization of other 
proxy variables, such as the Intelligent Quotient and occupational attainment, rather 
than educational years may be more helpful to investigate cognitive reserve in future 
studies. 
Compared to prior investigations, strengths of the present study included 
comprehensive assessments of vascular risk burden, a broad range of 
neuropsychological tests covering cognitive domains, and ascertainment of BD using 
a structured diagnostic interview. However, there were several methodological 
limitations that need to be considered when interpreting our findings. First, this study 
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was cross-sectional in design and direction of causation cannot be inferred. Second, 
there was no control group without BD included in this study, which make the results 
difficult to compare with general population. Third, the participants were recruited 
from psychiatric outpatient services and the distribution of MMSE total scores was 
higher than those reported in other studies of Taiwanese older patients with BD.2,5 Our 
sample may therefore represent a subgroup of older patients with BD who function 
relatively well in the community. Fourth, multiple comparisons were carried out to 
test the association of LOBD or other important variables with cognitive performance, 
which may lead to type I error. 
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5. Conclusion 
In summary, our data suggest that the later age of onset may not be associated 
with more severe cognitive dysfunction in older population with BD. In addition, we 
found that the higher serum homocysteine levels were significantly associated with 
worse cognitive performance in older patients with BD. Considering that patients with 
BD may have poor self-care ability and worse life quality at older age because of 
cognitive impairments, clinicians have to pay more attention to the cognitive function 
in older BD patients with higher levels of homocysteine. Further researches are 
warranted to investigate the role of homocysteine in the pathogenesis of 
neurocognitive deficits in patients with BD. 
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Tables 
Table 1. Comparison of sociodemographic and clinical characteristics between EOBD 
and LOBD 
 EOBD 
 (N=45) 
 LOBD 
 (N=50) 
  
Continuous variables Mean SD  Mean SD t P 
Age, years 62.3 3.7  63.8 5.9 -1.53 0.129 
Education, years 11.3 4.1  9.9 4.1 1.64 0.105 
Bipolar characteristics        
Age of first mania, years 30.0 14.1  53.3 7.1 -8.92 0.001 
Age of first depression, years 27.5 12.0  52.2 7.3 -9.14 0.001 
Duration of illness, years 38.4 9.1  11.3 8.1 15.35 0.001 
YMRS total score 3.4 2.7  3.7 3.2 -0.73 0.470 
HAMD total score 5.3 5.2  5.3 4.4 0.051 0.959 
Physical health status         
  Total number of symptoms 4.47 2.43  4.58 2.36 -0.23 0.818 
  Body mass index, kg/m2 26.7 3.7  25.3 3.9 1.78 0.079 
  Systolic blood pressure, mmHg 125.6 21.6  122.8 16.7 0.64 0.523 
Diastolic blood pressure, mmHg 78.1 12.4  72.5 10.7 2.19 0.031 
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  Fasting glucose levels, mg/dL 104.5 22.8  111.1 41.8 -0.94 0.349 
  Triglycerides levels, mg/dL 142.0 79.3  166.5 116.5 -1.18 0.242 
  Total cholesterol levels, mg/dL 185.7 39.0  203.5 43.4 -2.10 0.039 
  HDL-C levels, mg/dL 50.5 14.3  51.5 21.4 -0.28 0.781 
  Homocysteine levels, umol/L 15.0 6.2  12.2 4.2 2.56 0.012 
  Vitamin B12 levels, pg/mL 583.8 328.6  654.5 304.8 -1.10 0.287 
  Folate levels, ng/mL 12.0 4.5  10.6 4.3 1.42 0.158 
  Triiodothyronine levels, ng/ml 0.97 0.19  1.04 0.17 -1.85 0.068 
Category variables N %  N % χ2 p 
Male 22 48.9  29 58.0 0.79 0.374 
Married/widowed  33 73.3  32 69.6 2.51 0.102 
Current smoker 9 20.5  12 24.0 0.97 0.617 
Family history        
   Psychosis 5 11.9  11 22.4 1.74 0.188 
   Dementia 5 11.6  7 14.2 0.14 0.706 
Psychotropic medications        
Mood stabilizer 31 79.5  28 68.3 1.29 0.255 
   First generation antipsychotics 2 5.1  6 14.6 2.01 0.157 
Second generation antipsychotics 16 41.0  19 46.3 0.23 0.632 
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    Antidepressant 18 46.1  25 60.9 1.77 0.184 
Physical health status        
Angina 1 2.2  3 6.0 0.84 0.360 
Hypertension 20 44.4  20 40.0 1.04 0.596 
Diabetes mellitus 16 35.6  11 22.0 2.14 0.144 
Abbreviations: EOBD=early-onset bipolar disorder, HAMD=Hamilton Depression 
Rating Scale, HDL-C=high-density lipoprotein-cholesterol, LOBD=late-onset bipolar 
disorder, YMRS= Young Mania Rating Scale 
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Table 2. Comparison of cognitive functions between EOBD and LOBD 
 EOBD 
 (N=45) 
 LOBD 
 (N=50) 
  
Cognitive tests Mean SD  Mean SD  t P 
Total immediate recall 24.0 7.8  24.0 5.7 -0.03 0.977 
Delayed recall 4.5 3.0  4.5 2.4 -0.14 0.989 
Recognition 21.1 3.1  21.2 2.4 -0.20 0.842 
CTT-1, seconds 83.6 57.0  76.8 41.2 0.67 0.502 
CTT-2, seconds 143.1 65.7  146.2 63.2 -0.24 0.812 
Block design 24.8 11.6  24.4 10.2 0.17 0.865 
Verbal Fluency 12.0 4.5  12.5 4.1 -0.59 0.554 
DSST 44.1 19.1   42.7 17.4  0.39  0.700  
MMSE 26.3 3.2  25.9 2.7 0.60 0.549 
Abbreviations: CTT=Color Trail Test, DSST= Digit Symbol Substitution Test, 
EOBD=early-onset bipolar disorder, LOBD=late-onset bipolar disorder, MMSE= 
Mini-Mental State Examination 
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Table 3. Multiple linear regressions for the impact of explanatory variables on cognitive test parameters 
  Total immediate recall Delayed recall Recognition 
Explanatory variables B-coefficient β p value B-coefficient β p value B-coefficient β p value 
Age 0.10+0.16 0.08 0.531 0.13+0.07 0.23 0.062 0.02+0.07 0.05 0.737 
Gender -3.61+1.94 -0.26 0.067 -0.94+0.78 -0.17 0.233 -0.70+0.83 -0.13 0.404 
Years of education 0.79+0.19 0.47 0.001 0.27+0.08 0.39 0.001 0.19+0.08 0.29 0.023 
LOBD -4.40+3.00 -0.32 0.148 -2.19+1.21 -0.39 0.075 -1.21+1.29 -0.23 0.351 
Duration of illness -0.18+0.09 -0.41 0.061 -0.08+0.04 -0.45 0.037 -0.05+0.04 -0.29 0.221 
Framingham risk score -0.03+0.08 -0.06 0.686 -0.03+0.03 -0.14 0.343 -0.02+0.04 -0.07 0.656 
Homocysteine levels -0.18+0.15 -0.14 0.220 -0.15+0.06 -0.28 0.018 -0.05+0.06 -0.11 0.419 
Triiodothyronine levels  0.26+0.52  0.06 0.619  0.08+0.21  0.04 0.718  -0.03+0.22 -0.02 0.886 
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 CTT-1             CTT-2 Block design 
Explanatory variables B-coefficient β p value B-coefficient β p value B-coefficient β p value 
Age 0.85+1.09 0.09 0.437 3.51+1.36 0.29 0.012 -0.63+0.27 -0.28 0.023 
Gender 5.26+12.89 0.05 0.685 15.63+15.98 0.13 0.332 3.11+3.19 0.14 0.333 
Years of education -6.06+1.27 -0.51 0.001 -8.05+1.59 -0.52 0.001 1.12+0.31 0.40 0.001 
LOBD 19.86+19.99 0.20 0.324 19.61+24.82 0.16 0.432 -1.41+4.94 -0.06 0.776 
Duration of illness 0.86+0.62 0.28 0.171 0.68+0.77 0.17 0.381 -0.10+0.15 -0.14 0.508 
Framingham risk score -0.76+0.54 -0.19 0.168 -0.54+0.67 -0.11 0.428 -0.05+0.13 -0.05 0.716 
Homocysteine levels 2.54+0.99 0.28 0.013 1.98+1.23 0.17 0.114 -0.21+0.25 -0.10 0.386 
Triiodothyronine levels  2.96+3.46  0.09 0.396  0.60+4.31 0.01   0.890 0.01+0.86 0.01 0.990 
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 Verbal Fluency DSST MMSE 
Explanatory variables B-coefficient β p value B-coefficient β p value  B-coefficient β p value 
Age -0.11+0.11 -0.13 0.296 -1.14+0.38 -0.31 0.004 -0.11+0.07 -0.19 0.120 
Gender -0.38+1.26 -0.04 0.761 -0.08+4.47 -0.01 0.986 0.54+0.83 0.09 0.520 
Years of education 0.36+0.12 0.33 0.005 2.65+0.44 0.58 0.001 0.34+0.08 0.47 0.001 
LOBD -1.84+1.94 -0.21 0.346 2.18+6.93 0.06 0.754 -0.22+1.28 -0.04 0.862 
Duration of illness -0.09+0.06 -0.31 0.154 -0.02+0.26 -0.02 0.929 -0.01+0.04 -0.07 0.760 
Framingham risk score -0.01+0.05 -0.04 0.793 -0.05+0.19 -0.03 0.809 0.02+0.04 0.06 0.678 
Homocysteine levels -0.20+0.10 -0.25 0.041 -0.78+0.34 -0.23 0.026 -0.06+0.06 -0.11 0.333 
Triiodothyronine levels 0.41+0.34   0.14 0.230 0.58+1.20   0.05 0.631 -0.10+0.22 -0.05 0.661 
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Abbreviations: CTT=Color Trail Test, DSST= Digit Symbol Substitution Test, LOBD=late-onset bipolar disorder, MMSE= Mini-Mental State 
Examination  
